You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Cost recovery implementation statement, V1.1
Version 1.1 June 2017
The TGA consults with industry associations separately on regulatory matters and cost impacts relating to specific sectors. Industry associations are also consulted in the process of regulatory development and reform, and feedback is taken into account in developing regulatory impact statements, and in developing cost recovery arrangements. Meetings are held with key industry representative bodies each year to discuss financial forecasts and as a part of the consultation process on cost recovery. The TGA also reports to stakeholders against a set of agreed Key Performance Indicators (KPIs).
Consultation on the proposed changes to fees and charges for 2017-18 was undertaken at bilateral meetings with the following industry representative groups in February 2017:
- Medicines Australia
- Generic and Biosimilar Medicines Association
- Medical Technology Association of Australia
- IVD Australia
- Australian Dental Industry Association
- Australian Self Medication Industry
- Complementary Medicines Australia
- Accord Australasia.